Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Sunday share tips: Impact Healthcare, Wickes

(Sharecast News) - The Financial Mail on Sunday's Midas column recommended shares of Impact Healthcare, as 'a long-term buy', touting the company's long-term growth prospects, dividend yield of over 5.0% and management's attention to detail which they surmised was paying off. Impact owned 129 homes catering to more than 5,000 elderly residents who were cared for by the specialist care companies letting the homes.

Yet by 2030 the number of Britons aged over 85 was expected to jump by half to around 3.0m and, of those, about 15% would need to be looked after, preferably in residential or nursing homes.

Tenants were also meticulously vetted for their professionalism.

So too, homes were acquired with a view to a host of factors, including local demand and nearby availability of staff.

Management was also growing its roster of tenants slowly, curating it in order to ensure the quality of their finances.

Furthermore, two-thirds of residents were funded by NHS and local authorities, so that the majority of rents were government-backed.

Even so, Cowley and Patel also made sure that rents were affordable; hence their 100% rent collection rate even throughout the pandemic.

Not least, that had allowed the company to pay out "attractive" and rising dividends since Impact was listed on the market 2017.

In terms of the outlook, "strong" demand was expected with the company striving to improve its homes and having moved into development, meaning funding homes that have already been pre-let to tenants.

"Few people want to put their loved ones in a care home or end up in one themselves.

"Cowley and Patel are acutely aware of this and strive to make Impact's homes as warm and welcoming as possible.

"[...] The approach has worked well so far and should continue to do so."

The Sunday Times's Lucy Tobin highlighted the strengths of home improvement retailer Wickes over its much larger rival Kingfisher.

Foremost was the DIY chain's longstanding focus on value, which should stand it in good stead in the current cost and price environment.

Wickes had also invested heavily in its digital footprint and its core customers were older and wealthier and therefore better able to weather the current financial storm.

Hence why Sam Cullen at Peel Hunt said that it was "one of the most mispriced companies we cover" given that its shares were trading at roughly just six times expected earnings for 2022, which he said was "simply too cheap".

Kingfisher's boom on the back of Covid on the other hand had fizzled out, it was facing soaring costs, profits were expected to decline in 2022 and was trying to rightsize its 40 "vast" stores over the coming decade.

All told, that prompted to tell readers: "Something to do on your phone while queuing to buy paint this week: sell Kingfisher, buy Wickes."

Share this article

Related Sharecast Articles

Thursday newspaper round-up: Thames Water, mortgage costs, UK car production
(Sharecast News) - Thames Water has breached its licence to supply water to nearly 16 million people after some of its debt was downgraded to junk status. The regulator Ofwat could now fine Thames, the country's largest water monopoly, up to 10% of its annual turnover, equating to hundreds of millions of pounds. However, since the company is already teetering close to temporary renationalisation, Ofwat is likely to hold off on any immediate large fines. - Guardian
Wednesday newspaper round-up: Reckitt, Tesla, Virgin Atlantic...
(Sharecast News) - Reckitt is under pressure from top shareholders to revisit a sale of its nutrition business, following litigation and a series of other setbacks at the division that have sent the company's share price to decade lows. The FTSE 100 consumer giant acquired the Mead Johnson infant formula business in 2017 for $17bn - its largest-ever acquisition - and it has been plagued by mishaps ever since. Meanwhile, the wider group, which makes Lysol detergent and Durex condoms, has underwhelmed investors as it struggles to build back sales volumes following a period of high inflation and suppressed consumer demand. - Financial Times
Tuesday newspaper round-up: Kamala Harris, Crowdstrike, Vivendi...
(Sharecast News) - Kamala Harris has secured enough delegates from her party to clinch the Democratic presidential nomination, as she pledged to offer Americans a "brighter future" compared to the "chaos, fear and hate" proposed by Donald Trump. The US vice-president was speaking in Wilmington, Delaware, on Monday, the first full day since President Joe Biden dropped his re-election bid and endorsed her for the Democratic presidential nomination, shaking up the 2024 race for the White House. - Financial Times
Monday newspaper round-up: Biden, gambling levy, UK economy...
(Sharecast News) - Kamala Harris, the vice-president, has emerged as the frontrunner to replace President Biden as the Democratic nominee for the election against Donald Trump in November. Biden, 81, announced yesterday afternoon that he would drop out of the race. In the hours that followed, Harris, 59, was endorsed by leading Democrats, prospective rivals and the chairs of all 50 state parties. - The Times

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.